Loss of cBAF Complex Confers Sorafenib Resistance in Liver Cancer
Jacqueline A. Brinkman, Margarita M. Dzama, Max Bucklan…·Jesse R. Raab
This study identifies the cBAF complex as a driver of sorafenib resistance in liver cancer by disrupting hepatocyte lineage identity and promoting a mesenchymal drug-tolerant state.